Skip to main content

Table 2 Single-nucleotide polymorphisms associated with breast cancer risk with P values of less than 0.01a

From: The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort

 

All subjects

Premenopausal

Postmenopausal

 

Locus

WW

ca/co

WV

ca/co

VV

ca/co

OR

(95% CI)

P

PACTb

WW

ca/co

WV

ca/co

VV

ca/co

OR

(95% CI)

P

PACTb

WW

ca/co

WV

ca/co

VV

ca/co

OR

(95% CI)

P

PACTb

P int†

SLCO1B1

                   

rs11045773

898/857

401/468

50/67

0.83

(0.72-0.94)

0.0047

0.088

227/206

118/127

18/13

0.94

(0.72-1.21)

0.61

1.00

659/636

273/332

29/54

0.77

(0.65-0.90)

0.0009

0.020

0.17

rs11045777

899/855

401/471

50/64

0.83

(0.73-0.95)

0.0053

0.099

227/204

118/129

18/11

0.94

(0.73-1.22)

0.66

1.00

660/636

273/333

29/53

0.77

(0.65-0.90)

0.0009

0.019

0.17

rs976754

1,126/1,207

217/183

8/5

1.27

(1.03-1.55)

0.018

0.26

309/294

50/51

5/2

1.04

(0.71-1.53)

0.76

1.00

795/894

164/127

3/3

1.40

(1.10-1.79)

0.0046

0.077

0.15

rs16923519

836/921

452/421

62/53

1.17

(1.02-1.33)

0.018

0.26

244/222

107/114

12/11

0.92

(0.70-1.20)

0.53

1.00

577/685

335/297

50/42

1.26

(1.08-1.47)

0.0019

0.038

0.029

rs4149057

496/569

641/638

209/186

1.14

(1.02-1.27)

0.021

0.28

152/133

164/172

48/42

0.96

(0.77-1.19)

0.70

1.00

334/429

466/453

157/140

1.22

(1.07-1.39)

0.0024

0.046

0.047

rs4149058

778/854

468/467

95/72

1.15

(1.02-1.30)

0.029

0.34

220/204

122/120

21/22

0.94

(0.73-1.20)

0.66

1.00

541/636

342/337

71/50

1.23

(1.07-1.43)

0.0043

0.074

0.052

rs11045884

880/871

412/452

41/63

0.86

(0.75-0.99)

0.031

0.36

216/220

126/107

15/16

1.09

(0.84-1.42)

0.42

1.00

649/638

277/335

25/46

0.78

(0.66-0.92)

0.0023

0.044

0.033

rs11045825

953/943

357/394

38/55

0.87

(0.75-1.00)

0.045

0.45

237/236

112/97

14/13

1.09

(0.83-1.42)

0.54

1.00

700/692

237/288

23/42

0.79

(0.66-0.93)

0.0040

0.068

0.037

rs10841767

889/874

411/451

49/67

0.88

(0.77-1.00)

0.049

0.47

221/222

125/107

17/18

1.07

(0.83-1.38)

0.51

1.00

653/639

277/334

31/48

0.80

(0.69-0.94)

0.0059

0.091

0.058

rs11045813

917/918

372/401

37/56

0.88

(0.76-1.01)

0.068

0.58

225/229

118/99

13/12

1.12

(0.85-1.47)

0.40

1.00

677/676

245/293

23/44

0.79

(0.67-0.94)

0.0051

0.082

0.024

HSD17B4

                   

rs382719

393/457

672/685

275/241

1.16

(1.04-1.29)

0.0084

0.097

105/124

179/172

76/51

1.32

(1.06-1.64)

0.012

0.12

282/329

479/499

194/184

1.11

(0.98-1.26)

0.11

0.657

0.16

rs17388769

919/1,002

393/364

33/21

1.21

(1.04-1.41)

0.012

0.13

243/258

108/89

11/0

1.56

(1.15-2.13)

0.004

0.051

656/729

280/266

22/21

1.12

(0.94-1.34)

0.15

0.77

0.074

  1. aSingle-nucleotide polymorphisms associated with breast cancer risk with P values of less than 0.01 (uncorrected for multiple testing) in either overall analyses or subgroup analyses of premenopausal or postmenopausal women. The odds ratios (ORs) and 95% confidence intervals (CIs) were based on conditional logistic regression models stratified by age group (within 5-year age groups) and specimen collection centers - the Cancer Prevention Institute of California, the University of Southern California, and the University of California at Irvine - using log-additive genetic models. bPACT (P value adjusted for correlated tests) within each gene was calculated by using the methods of Conneely and Boehnke [68]. When PACT values were applied across all genes evaluated, none of the values was statistically significant. c P values for interaction.
  2. CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.